| |||
1. (B) |
®Ú¾Ú¤¤µØ¥Á°ê¤ßŦ¾Ç·|©ó2007¦~°w¹ï ¡§ST¸`¬q¤W¤É«æ©Ê¤ß¦Ù±ð¶ëªvÀø«ü¤Þ¡¨ ¤¤¡A¹ï©Ò¦³ªº«æ©Ê¤ß¦Ù±ð¶ë±wªÌ¡A«Øij¶·§Ö³tµû¦ô¦AÄéª`ªvÀø¤§¿ï¾Ü¤Î¬ÛÃöÃÄ«~ªºªvÀø¡A¨ä¤¤¡A¦b§Ü¦å®êÃÄ«~ªvÀø¤¤¡AY¯f±wµL§Ü¦å®êÃÄ«~ªº¸T§Ò¡A¥²¶·¨Ï¥ÎÀR¯ß©Î¥Ö¤U¶Ç²Î¨x¯À©Î¥Ö¤U§C¤À¤l¶q¨x¯À¦Ü¤Ö´X¤p®É? | ||
A | 72¤p®É | ||
B | 48¤p®É | ||
C | 24¤p®É | ||
D | 36¤p®É | ||
2. (D) |
¤U¦CÃö©ófondaparinuxªº´yz¡A¦óªÌ¿ù»~? | ||
A | Fondaparinux¦b»OÆW©Ò®Öã³q¹Lªº¾AÀ³¯g¬° ¡§¹w³Æ±µ¨ü°©¬ì¤UªÏ¤â³N (Æb°©°©§é¡A½¥Ãö¸`©ÎÆbÃö¸`¸m´«¤â³N) ¤§ÀR¯ß¦å®ê°ª¦MÀI¸s (´¿µo¥Í¦³¯gª¬¤§ÀR¯ß¦å®ê¯g) ±wªÌµo¥ÍÀR¯ß¦å®ê®ê¶ë¨Æ¥ó (VTE)¡CªvÀøST¬q¤É°ª«¬¤ß¦Ù±ð¶ëªº«æ©Ê«aª¬¯gÔ¸s¡AÂÇ¥H¹w¨¾¨Ï¥Î¦å®ê·»¸Ñ¾¯ªvÀø©Îì¥ý§Y¤£·Ç³Æ±µ¨ü¥ô¦ó¨ä¥¦«¬¦¡¤§¦AÄé¬yªvÀøªº±wªÌµo¥Í¦º¤`©M¤ß¦Ù¦A«×±ð¶ë¡¨ | ||
B | Fondaparinux¬°¦X¦¨ªºpentasaccharide¡A¥i¿ï¾Ü©Êªº§í¨î²ÄXa¦]¤l | ||
C | ¹ï©ó¤£¾A¨Ï¥Î¶Ç²Î¨x¯Àªº«æ©Ê«aª¬°Ê¯ß¯gÔ¸s±wªÌ¡Afondaparinux¬O§Ü¾®¦å¾¯ªº¥t¤@Ó·s¿ï¾Ü | ||
D | Fondaparinux¦b»OÆW©Ò®Öã³q¹Lªº¾AÀ³¯g¤]¥]¬AªvÀø«DST¬q¤É°ª«¬¤ß¦Ù±ð¶ëªº«æ©Ê«aª¬¯gÔ¸s | ||
3. (B) |
½Ð±Æ§Ç§l®ð¦Ù¦×ªº¯h³Ò·|¨Ì§Ç¥X²{¦óºØÅܤơH(a)¦å¤¤¤G®ñ¤ÆºÒ¤ÀÀ£ªº¤W¤É¤Î©I§l»Ä¤¤¬r¡A(b)©I§l³t²v¤Î¨C¤ÀÄÁ´«®ð¶qªº´£°ª¡A(c)¯Ý¸¡©I§l¹B°Ê¤Ï±`(abdominal paradox) (d)Åéªí¦Ù¹q¹ÏªºÅܤơC | ||
A | (a)(b)(c)(d) | ||
B | (d)(b)(c)(a) | ||
C | (b)(a)(c)(d) | ||
D | (c)(b)(a)(d) | ||
4. (D) |
¦óªÌ¤£¬O¥Í²z´ú¶q©I§l¥\ªº¤èªk? | ||
A | ©I§l®ñ¯Ó(oxygen cost of breathing) | ||
B | §¢¨©º¸¹Ï(Campbell’s diagram) | ||
C | À£¤O®É¶¡¼¿n(pressure time product) | ||
D | «ùÄòªÍ°Ê¯ß¼öµ}ÄÀ(continuous PA thermodilution) | ||
5. (B) |
Ãö©ó«æ©ÊB«¬¨xª¢ªºªvÀø¡A¦óªÌ¬°«D¡G | ||
A | 95%ªº«æ©ÊB«¬¨xª¢¬°¦Û©Ê(self-limited)¡AµL»Ý¯S§OªvÀø | ||
B | ¤@¥¹Á`Áx¬õ¯À>2mg/dL¡A¥²¶·¥ß§Y§ë¤©¤fªA§Ü¯f¬rÃĪ« | ||
C | ÄY«ªº«æ©ÊB«¬¨xª¢¸g¤fªA§Ü¯f¬rÃĪ«ªvÀø¥i¯à¥i°§C¦º¤`©M¨x²¾´Ó²v | ||
D | «æ©ÊB«¬¨xª¢¸g¤z¦w¯àªvÀø¥i¯à·|¤zÂZB«¬¨xª¢ªí±§ÜÅé²£¥Í | ||
6. (D) |
¥i§Q¥Î¤U¦C¿ï¶µ°Ï§O«æ©ÊB«¬¨xª¢»PºC©ÊB«¬¨xª¢«æ©Êµo§@¡A¦óªÌ¬°«D: | ||
A | anti-HBc IgM >1:1000©Î1:10000 | ||
B | HBV DNA <100000 copies/mL | ||
C | AFP<5¿¥¿±`¤W | ||
D | HBeAg³±©Ê | ||
7. (C) |
®Ú¾Ú¥Ø«eÁ{§É¬ã¨s¡A¤U¦C¹ï¥v¶ð¤BÃþ°¦å¯×ÃĪ«ªº±Ôz¡A¦óªÌ¬°«D¡H | ||
A | ®Ú¾Ú¾ã¦X¤ÀªRµ²ªGÅã¥Ü¡A¥v¶ð¤B¥i¯à²¤¼W¥[·s¶EÂ_¿}§¿¯fªº¾÷·| | ||
B | ¹ï©ó¿}§¿¯f¯f¤H¦Ó¨¥¡A¥v¶ð¤B¨Ï¥Î¥i¯à·|¼vÅT¦å¿}±±¨î | ||
C | Áx»Äµ²¦X¾ð¯×¸û¤£·|¼vÅT¦å¿}ÅܤơA¦]¦¹À³¸ÓÀu¥ý¨Ï¥Î | ||
D | ¥v¶ð¤Bªº¨Ï¥Î¦n³B¤j©óÃa³B¡A¦³¥²n®É¤´«Øij¨Ï¥Î | ||
8. (D) |
°ª¦å¯×¯f¤H¦b°¦å¯×ÃĪ«ªº¨Ï¥Î«Øij¡A¤U¦C¦óªÌ¬°¬O¡H | ||
A | Y¯f¤H³B©ó¿}§¿¯f«e´Á¡A«h«Øij¤£¥i¨Ï¥Î°¦å¯×ÃĪ« | ||
B | Y¯f¤H¤w±o¨ì¿}§¿¯f¡A«h«Øij¤£¥i¨Ï¥Î°¦å¯×ÃĪ« | ||
C | ¿}§¿¯f¯f¤HY¦å¿}Ãø¥H±±¨î¡A«h«Øij¤£¥i¨Ï¥Î°¦å¯×ÃĪ« | ||
D | ¥un©w®ÉºÊ±±¦å¿}ÅܤơA¤´¥i¦w¤ß¨Ï¥Î¦UºØ°¦å¯×ÃĪ« | ||
9. (D) |
§C¦å¿}¥i¯à³y¦¨¤ß¦åºÞ¨Æ¥óªº¾÷Âà¦óªÌ¬°«D? | ||
A | ¥æ·PµÇ¤W¸¢ªº¬¡¤Æ | ||
B | µoª¢¤ÏÀ³ | ||
C | ¤º¥Ö²ÓM¥\¯à²§±` | ||
D | ¦å¤¤¯Ø®q¯À¿@«×¹L°ª | ||
10. (D) |
§C¦å¿}»P¤ß¦åºÞ¯e¯fªºÃö«Y¡A¤U¦C¦óªÌ¬°¬O? | ||
A | §C¦å¿}·|ª½±µ³y¦¨¤ß¦åºÞ¯e¯f¤w¦³¥R¤ÀªºÃÒ¾Ú | ||
B | §C¦å¿}»P¤ß¦åºÞ¯e¯f§¹¥þ¨S¦³ÃöÁp | ||
C | ACCORD study¤¤ÄY®æ¦å¿}±±¨î²Õ¥ô¦óì¦]ªº¦º¤`²v¸û¤@¯ë¼Ð·Ç±±¨î²Õ°ª¡A¥i¥Î§C¦å¿}¨Ó¸ÑÄÀ | ||
D | §C¦å¿}©M¤ß¦åºÞ¯e¯f¦³Ãö¡A¦ý¦]ªGÃö«Y©|¥¼½T¥ß | ||
11. (D) |
¦³Ãö«¯g±wªÌ²£¥Í°ª¦å¿}¤§¯f²z¥Í²z¾÷Âà¡A¤U¦C±Ôz¦óªÌ¬°»~¡G | ||
A | À£¤O©Ê°ª¦å¿}¯g( Stress induced hyperglycemia)¬O«¯g¯f±w²£¥Í°ª¦å¿}ªº¥Dnì¦] | ||
B | À£¤O©Ê°ª¦å¿}¯gªº§Î¦¨¾÷Âà¥Dn¦³¨â¤j¦¨¦]¡G¡u¤º¥Í©Ê²üº¸»X½Õ±±¦å¿}§@¥Î¡v¥H¤Î¡u²ÓM¿E¯À§@¥Î²£¥Í¯Ø®q¯Àªý§Üªº¼W¥[¡v | ||
C | µoª¢¤ÏÀ³©ÒÄÀ©ñ¥X¨Óªº²ÓM¿E¯À¡A¦p¸~½FÃa¦º¦]¤l(TNF-a)¡BIL-1b¡BIL-6µ¥¡A·|Âǥѽձ±¤º¥Í©Ê²üº¸»X(¦pª@ÁÞ¯À, µÇ¤W¸¢¯À, µÇ¤W¸¢¥Ö½è¯Àµ¥)¼W¥[¸²µå¿}ªº»s³y¡A¨Ï¯Ø®q¯À¬Û¹ï¤£¨¬ | ||
D | ¯Ø®q¯À½Õ±±¦å¿}¦^¦¬§@¥Î¸ô®|³Q§í¨î(¦pGLUT-4 translocationªº¯Ê¥¢)»P«¯g±wªÌ²£¥Í°ª¦å¿}¸ûµL¬ÛÃö©Ê | ||
12. (D) |
¥Ñªñ10¦~¨Óªº¬ã¨s¤åÄm¡A¹ï©ó«¯g±wªÌ¤§¦å¿}±±¨î¬ã¨s¡A¤U¦C±Ôz¦óªÌ¬°¯u¡G | ||
A | 2001¦~Leuven studyªºµ²ªGÅã¥Ü¡G¡u¨Ï¥Î¯Ø®q¯ÀÄéª`±N¦å¿}±±¨î¦b80-110 mg/dL¤§¶¡¡A¥i¥H°§C¤º¬ì¯f±w¦º¤`²v¡v | ||
B | 2008 de la Rosa G study¥H¤Î2008 Arabia study±N¤º¥~¬ì¥[Å@¯f©Ð¦í°|¯f±w¤@°_±´°Q¡Aµ²ªG¤]¤ä«ùÄY®æ¦å¿}±±¨î¥i¥H°§C¯f±w¦º¤`²v | ||
C | 2009¦~·s^®æÄõÂø»xªºNICE-SUGAR studyªºµ²ªGÅã¥Ü¡G¡uÄY®æ±±¨î¦å¿}©ó81-108 mg/dL¥[Å@¯f©Ðªº¯f±w¡A¨ä90¤Ñ¤º¦º¤`²v©úÅã§C©ó¦å¿}±±¨î¦b¡Ø180 mg/dLªº¯f±w¡v | ||
D | 2010¦~¬ü°ê¿}§¿¯f¾Ç·|©Òµoªíªº¡u2010¦~¿}§¿¯fªvÀø«ü¤Þ¡v¹ï©ó«æ«¯g±wªÌ¦å¿}±±¨î«Øij¦p¤U¡G¡u¤£À³¸Ó¶W¹L180 mg/dL¡A¹ï©ó¤j¦h¼Æªº«¯g±wªÌÀ³¸Ó±±¨î¦b140-180 mg/dL | ||
13. (C) |
Ãö©ó§xÃø±ôª¬±ìµßªvÀø¡A¥H¤U¦óªÌ¬O¿ù»~ªº¡H | ||
A | «Øij°±¤î¤£»Ýnªº§Ü¥Í¯À | ||
B | °w¹ï«DÄY«¯f±w¡A¥i¥H¦Ò¼{¨Ï¥Î¥ÒµvÐü(metronidazole)ªvÀø | ||
C | °w¹ïÄY«·P¬V¯f±w¡A¥²¶·ª`®g¸U¥jÅð¯ÀªvÀø | ||
D | ¥²¶·¾A«×¸É¥R¤ô¤À¥H¤Î¹q¸Ñ½è | ||
14. (D) |
Ãö©ó§xÃø±ôª¬±ìµß´yz¡A¥H¤U¦óªÌ¿ù»~¡H | ||
A | ±`±`¸g¥ÑÂåÅ@¤HûÂù¤â¶Ç¬V | ||
B | ªvÀø§xÃø³B¦b©ó´_µo²v«Ü°ª | ||
C | °w¹ïÃĪ«ªvÀø¥¢±Ñ¯f±w¡A¥i¯à»Ýn¦Ò¼{¶}¤MªvÀø | ||
D | «ØijÂåÅ@¤Hû±`±`¥H°sºë¬~¤â¡A¥H²M°£¨äÌU¤l | ||
15. (C) |
Which one of the followings not included in the classic triad of rhabdomyolysis? | ||
A | myalgia | ||
B | dark urine | ||
C | neuralgia | ||
D | muscle weakness | ||
16. (D) |
Which one of the followings not included in the mechanism of acute renal injury induced by rhabdomyolysis? | ||
A | tubular obstruction | ||
B | vasoconstriction | ||
C | toxic effect of iron on tubule | ||
D | serum CK level |